Neurological effects of psychopharmacological agents.
Fann
Jesse R
JR
Department of Psychiatry, University of Washington, Seattle, WA, USA.
D000368:Aged; D014151:Anti-Anxiety Agents / Q000627:therapeutic use; D000928:Antidepressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D018692:Antimanic Agents / Q000627:therapeutic use; D000978:Antiparkinson Agents / Q000009:adverse effects / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000627:therapeutic use; D002037:Bundle-Branch Block / Q000150:complications / Q000523:psychology; D003693:Delirium / Q000209:etiology / Q000523:psychology; D003866:Depressive Disorder / Q000150:complications / Q000523:psychology; D006801:Humans; D008094:Lithium / Q000627:therapeutic use; D008297:Male; D009422:Nervous System Diseases / Q000188:drug therapy* / Q000523:psychology*; D010300:Parkinson Disease / Q000150:complications / Q000523:psychology; D011619:Psychotropic Drugs / Q000009:adverse effects / Q000627:therapeutic use*; D012642:Selegiline / Q000009:adverse effects / Q000627:therapeutic use
D014151:Anti-Anxiety Agents; D000928:Antidepressive Agents; D018692:Antimanic Agents; D000978:Antiparkinson Agents; D014150:Antipsychotic Agents; D011619:Psychotropic Drugs; D012642:Selegiline; D008094:Lithium